Previous close | 104.00 |
Open | 104.10 |
Bid | 104.45 x N/A |
Ask | 105.32 x N/A |
Day's range | 104.00 - 104.64 |
52-week range | 101.81 - 106.95 |
Volume | |
Avg. volume | 7,470 |
Market cap | N/A |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 5.40 (5.19%) |
Ex-dividend date | 13 June 2024 |
1y target est | N/A |
PALO ALTO, Calif., April 03, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.